Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report)'s stock price was down 2.8% during trading on Thursday . The stock traded as low as $4.50 and last traded at $4.59. Approximately 397,013 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 1,234,237 shares. The stock had previously closed at $4.72.
Wall Street Analyst Weigh In
Separately, Wall Street Zen cut Dominari from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd.
Get Our Latest Stock Report on DOMH
Dominari Stock Down 2.8%
The company has a 50 day moving average of $4.60 and a 200 day moving average of $3.90. The firm has a market cap of $65.31 million, a price-to-earnings ratio of -1.15 and a beta of 0.59.
Dominari (NASDAQ:DOMH - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $0.20 EPS for the quarter. Dominari had a negative return on equity of 32.89% and a negative net margin of 180.22%. The business had revenue of $6.56 million for the quarter.
Institutional Trading of Dominari
A hedge fund recently raised its stake in Dominari stock. Renaissance Technologies LLC raised its position in shares of Dominari Holdings Inc. (NASDAQ:DOMH - Free Report) by 20.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,326 shares of the company's stock after buying an additional 9,400 shares during the quarter. Renaissance Technologies LLC owned about 0.89% of Dominari worth $55,000 at the end of the most recent quarter. Institutional investors own 42.48% of the company's stock.
About Dominari
(
Get Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Recommended Stories
Before you consider Dominari, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.
While Dominari currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
